Iceland launches massive screening study for early cancer detection

NCT ID NCT03327597

First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 30 times

Summary

This study is screening over 80,000 people in Iceland to see if early detection of a condition called MGUS can prevent or improve outcomes for multiple myeloma, a type of blood cancer. Participants are randomly assigned to routine care or closer monitoring. The goal is to compare survival and complications between the groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University of Iceland

    Reykjavik, Iceland

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could show that population-wide screening for MGUS helps catch multiple myeloma earlier, potentially improving survival and reducing treatment complications.

What could go wrong

This is an observational screening study, not a treatment trial. It may not prove that screening saves lives, and there is a risk of overdiagnosis or unnecessary anxiety.

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.